Effects of the somatostatin analogue SMS 201–995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man

Publisher Website
Google Scholar
Abstract
Somatostatin analogues, such as SMS 201-995 (sandostatin), have been suggested as treatment for a variety of disease states including acromegaly, secretory gastrointestinal tumours and diabetes mellitus. Somatostain-14 has actions to prolong gastrointestinal transit time and inhibit intestinal absorption, and we have therefore studied the effects of SMS 201-995 on these processes. Five male subjects received a test meal having been given either saline or 50 .mu.g of SMS 201-995 subcutaneously 30 min before ingestion. SMS 201-995 caused a delay in mouth-to-caecum transit time for lactulose assessed by breath hydrogen analysis (316 .+-. 17 vs 192 .+-. 14 min, mean .+-. SEM, P < 0.01), a delay (234 vs 120 min, P < 0.05) in the plasma peak of the non-metabolizable glucose analogue 3-O-methylglucose and conversion of the expected postprandial rise in serum triglycerides (with saline 1.02 .+-. 0.20 to 1.51 .+-. 0.28 mmol/l, P < 0.05) to a decrease below basal values (with SMS 201-995 0.97 .+-. 0.80 to 0.79 .+-. 0.11 mmol/l, P < 0.05). After SMS 201-995, an enhancement of the increase in blood glucose (8.2 .+-. 0.7 vs 4.7 .+-. 0.2 mmol/l, P < 0.01) and inhibition and postponement of the postprandial rise in insulin (27.6 .+-. 6.7 vs 9.9 .+-. 2.1 m-units/l, P < 0.05) occurred. Furthermore, a rise in non-esterified fatty acids, glycerol and 3-hydroxybutyrate, compared with the decline in concentrations of these metabolites after saline, was observed. We conclude that SMS 201-995 has actions to increase mouth-to-caecum transit time, to diminish the rate of active monosaccharide absorption and to lower basal and postprandial triglyceride levels. These effects probably relate to inhibition of exo- and endocrine gastrointestinal secretion.